RxDoctor Payments Data

Tina Mayer, MD

Medical Oncology · New Brunswick, NJNPI 1598931420

Payments from drug & device makers

What this record shows

6 manufacturers reported payments, led by Exelixis Inc. at 38.0% of the total. 2025 is the largest year on record at $4,123, 3.2 times the $1,270 reported in 2019.

$10,415in general payments, 2019–2025

Across 8 payments — averaging $1301.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$4K
  • Janssen Global Services, LLC$2K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • Blue Earth Diagnostics$1K
  • Janssen Scientific Affairs, LLC$880
$549,838in research payments, 2019–2025

Across 37 payments — averaging $14,860 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$550K

What the payments were for

  • Consulting fees$5,18550%
  • Speaking & faculty fees$5,23050%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,415 in reported general payments places this provider in the 70th percentile of 112 medical oncology providers in New Jersey.

See all medical oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$61,694
Medicare patients
174
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide77$1,071,210
NubeqaDarolutamide35$443,426
Abiraterone Acetate184$192,685
OrgovyxRelugolix12$31,262
EliquisApixaban16$8,980
Bicalutamide66$1,651
Prednisone142$592
Tamsulosin Hcl39$409
Venlafaxine Hcl ErVenlafaxine Hcl26$228
Levothyroxine Sodium13$202
Dexamethasone23$181
Gabapentin17$138
Ondansetron Hcl12$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Janssen Scientific Affairs, LLCAbiraterone Acetate$880$192,685184 claims
PfizerEliquis$1,270$8,98016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 112 medical oncology providers in New Jersey.

Other medical oncology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →